CMS
HHS Releases List of Medicare Part B Drugs Subject to Rebate Program
The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.
Vertex Pharmaceuticals, Bluebird Bio to Participate in CMS Cell and Gene Therapy Access Model
CMS has negotiated outcomes-based agreements for sickle cell gene therapies with the two companies on behalf of participating state Medicaid programs.
CMS Rolling Out New Payment Policy for High-Cost Diagnostic Radiopharmaceuticals
The government payor said it will separately pay for specialized diagnostic radiopharmaceuticals without transitional pass-through payment status.
Cofactor Genomics Immunotherapy Response Test Nabs Medicare Coverage
The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.
Tempus Nabs CMS Advanced Diagnostic Laboratory Test Status for Tumor Mutation Profiling Test
The xT CDx is a next-generation sequencing-based assay that is used for the detection of substitutions, insertions, and deletions and microsatellite instability status.
Nov 30, 2023
Sep 21, 2023